GU Cancers 2024 | Real-world survival and recurrence risk in patients with RCC

Viktor Grünwald, MD, University Hospital Essen, Essen, Germany, gives an overview of real-world outcomes of patients with operable renal cell carcinoma (RCC) from the German translational cancer research consortium (DKTK) network. Patients with different subtypes such as clear cell and papillary RCC were eligible, and morphology and T-stages were found to affect outcomes in terms of overall survival and risk of recurrence. This interview took place at the ASCO GU Cancers Symposium 2024 in San Francisco, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.